Industry Newsroom

3W Fund Management Leads USD43m Series E for Chinese Drug Developer CANbridge Pharma

3W Fund Management led a USD43m Series E for China-based drug developer CANbridge Pharmaceuticals, with participation from Casdin Capital, Summer Capital, SPDBI, and Yaly Capital, and follow-on from Hudson Bay Capital, RA Capital, Lyfe Capital, and Tigermed. Read more